UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)

Core Insights - Alvotech has successfully defended against infringement proceedings initiated by Regeneron Pharmaceuticals and Bayer AG, allowing the company to continue manufacturing its biosimilar AVT06 in the UK [1][2] - The UK High Court's decision supports Alvotech's commercial launch of AVT06 in the European Economic Area and other regions following the expiry of Supplementary Protection Certificates for Eylea® on November 23, 2025 [1][2] - The approval of AVT06 as a biosimilar to Eylea® by the European Commission and the UK Medicines and Healthcare products Regulatory Agency (MHRA) further strengthens Alvotech's market position [3] Company Overview - Alvotech is a biotech company focused on developing and manufacturing biosimilar medicines globally, aiming to be a leader in the biosimilar market by providing high-quality, cost-effective products [5] - The company has two biosimilars already approved and marketed, with a pipeline of nine additional candidates targeting various diseases, including autoimmune disorders and cancer [5] - Alvotech has established strategic partnerships with multiple global companies to enhance its market reach and leverage local expertise [5] Product Information - AVT06 (aflibercept) is a recombinant fusion protein approved as a biosimilar to Eylea®, which inhibits vascular endothelial growth factors [4] - The product is currently under review in several countries, including the United States, indicating potential for further market expansion [4]